<DOC>
	<DOCNO>NCT01837693</DOCNO>
	<brief_summary>In industrialized country , cervical cancer well control disease thanks diffusion Pap test , particular , organize screening program , able detect treat pre-invasive lesion ( cervical intraepithelial neoplasia , CIN ) . The human papilloma virus ( HPV ) recognise necessary , sufficient , cause cervical cancer , new screen test base identification high risk ( HR ) HPV type develop ( HPV DNA test ) . This test demonstrate effective cytology reduce incidence mortality cervical cancer , less specific , use test triage necessary reduce number colposcopies risk over-diagnosis ( due potential regressivity pre-invasive lesion ) . Until , triage test use cytology ( Pap test ) . Recently specific biomarkers ( mRNA p16 test ) introduce high grade CIN , target molecular alteration strictly associate transformation rather simply detect HR-HPV infection . These test specific HPV DNA test modest reduction sensitivity high-grade lesion . This multicenter randomise trial nested Italian screen program base use HPV DNA test primary test . All woman positive HPV DNA test test cytology also mRNA p16 . Women positive cytology refer colposcopy , woman negative cytology randomize two arm . This study aim evaluate mRNA p16 could use test triage HPV DNA primary screen test direct sending colposcopy . In particular main objective : - Measuring cumulative detection rate CIN2+ five year follow HPV DNA positive test mRNA p16 negative . - Measuring potential reduction overdiagnosis use mRNA p16 test instead DNA , direct send colposcopy - Measuring reduction overdiagnosis cytological triage triage mRNA p16 compare direct send colposcopy woman HPV DNA test positive . Secondary objective : - ass feasibility mRNA test primary screen - validate sample techniques new test - standardize quality control new test</brief_summary>
	<brief_title>Cervical Cancer Prevention : From DNA mRNA ? - New Technologies Cervical Cancer Screening 2</brief_title>
	<detailed_description>Individual data follow study step collect accord fix format : 1. recruit woman 2 . HPV DNA result 3. cytology randomization result 4. p16 result 5. mRNA result 6. colposcopies ( relative cytology histology ) result 7 . Women exclude informed consent 8 . Interventions During first year recruitment , two semi-annual send data , year . To analyze study progress center , summary table periodically send PI . All CIN lesion cancer find study blindly review . A set quality assurance procedure implement molecular test , include use control provide manufacturer know HPV DNA mRNA content circulation clinical sample prepared laboratory participate study .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Precancerous Conditions</mesh_term>
	<criteria>woman invite new screen round base HPV DNA test woman resident screen area , pregnant , treat CIN 5 previous year , postcolposcopy follow , repetition unsatisfactory cytology .</criteria>
	<gender>Female</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>cervical cancer screen</keyword>
	<keyword>CIN</keyword>
	<keyword>cervical cancer</keyword>
	<keyword>biomarkers</keyword>
	<keyword>sensitivity specificity</keyword>
</DOC>